Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 301, Issue 2, 2002, Pages 507-512

  Dalton, James T ^a,b,c,d   Yates, Charles R ^a,b,c,d   Yin, Donghua ^a,b,c,d   Straughn, Arthur ^a,b,c,d   Marcus, Stuart L ^a,b,c,d   Golub, Allyn L ^a,b,c,d   Meyer, Marvin C ^a,b,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c DUSA Pharmaceuticals Inc   (United States)

^d Guidelines Integrated Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; PRODRUG; PROTOPORPHYRIN;

AREA UNDER THE CURVE; ARTICLE; BLADDER; BLADDER CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; HIGH RISK PATIENT; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RECURRENT CANCER; VOLUNTEER;

ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; AMINOLEVULINIC ACID; CROSS-OVER STUDIES; DRUG ADMINISTRATION ROUTES; HUMANS; INJECTIONS, INTRAVENOUS; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; RECURRENCE; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0036226359     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.301.2.507     Document Type: Article

References (17)

1. Photodynamic therapy for dysplastic Barrett's oesophagus: A prospective, double blind, randomised, placebo controlled trial
2. Methods to improve efficacy of intravesical mitomycin c: Results of a randomized phase III trial
3. Analysis of the porphyrin content of fluorescent pus by absorption spectrephotometry and HPLC
4. Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs
5. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients
6. Pharmacokinetics of aminolevulinic acid after intravesical administration to dogs
7. Physiological parameters in laboratory animals and humans
8. Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid
9. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy
10. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence
11. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy
12. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA). Current clinical and development status
13. Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX
14. 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: Pharmacokinetics after oral or intravenous administration
15. Determination of very small amounts of protoporphyrin in epidermis, plasma, and blister fluids
16. Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid
17. A method to study drug concentration-depth profiles in tissues: Mitomycin c in dog bladder wall